Cell Therapeutics, Inc. (NASDAQ:CTIC)
| CAPS Rating |
|
|---|---|
| Open | $1.09 |
| Previous Close | $1.10 |
| Daily Range | $1.07 - $1.09 |
| 52-Week Range | $0.95 - $3.33 |
| Market Cap | $208.23M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,023,270 |
| Average Daily Volume | 0 |
CTIC
VS S&P 500 (SPY)
How do you think CTIC will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CTIC Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CTIC News and Commentary
- The Skinny on Upcoming Obesity FDA Meetings – The Motley Fool
- What's Going on With These Biotech Stocks? – The Motley Fool
- Hasn't Cell Therapeutics Ever Heard of All-Nighters? – The Motley Fool
- FDA Pharma Meetings for February – Blogs @ The Motley Fool
- This Biotech is Going Global – The Motley Fool
- The Most Important Thing for This Biotech – The Motley Fool
- Buy, Sell, or Hold: Cell Therapeutics – The Motley Fool
- The Magic Formula for Biotech – The Motley Fool
- Mark Your Calendars, Biotech Investors – The Motley Fool
- US Panel to Review CTIC's Pixantrone - Analyst Blog – NASDAQ
- 2011 Review: Cell Therapeutics – The Motley Fool
- 3 Stock-Moving Binary Events to Watch in 2012 – The Motley Fool
- The Worst Health Care Stocks of 2011 – The Motley Fool
- Is 2012 Make or Break for Cell Therapeutics? – The Motley Fool
- 3 Biotech Stocks That Had a Bad 2011 – The Motley Fool
- What's Up With the Back-Slapping, Sequenom? – The Motley Fool
- Cell Therapeutics' Wild Week – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- 1 Biotech Soars While Another Crashes – The Motley Fool
- Mid-Day Update: Stocks Higher; Investors Cheer European Fiscal Deal – NASDAQ
RSS Headlines
Fool UK
